Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01459666 · ClinicalTrials.gov registry record · Phase 4
Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer
A Phase 4 study, sponsored by University Hospitals Cleveland Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 9
- Enrollment target
NCT01459666 is a Phase 4 study that was terminated before completion, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 9 participants.
The verdict
NCT01459666, a Phase 4 study, was terminated before completion, sponsored by University Hospitals Cleveland Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study will test if the use of DysportTM (abobotulinumtoxinA) improves wound healing and scarring after Mohs surgery. Research in the laboratory as well as previous studies in humans have shown improved wound healing and scarring with the use of a similar medication called Botox. Dysport may improve wound healing and scarring by relaxing facial muscles and therefore minimizes the muscle tension and possibly the inflammation around the wound.
Interventions
- DRUG Dysport (abobotulinumtoxinA)
- DRUG Bacteriostatic 0.9% Sodium Chloride (vehicle)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2011-09 |
| Est. Completion | 2019-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01459666
The ClinicalTrials.gov registry entry for NCT01459666 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University Hospitals Cleveland Medical Center, which has 230 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dysport (abobotulinumtoxinA) is the first listed.
NCT01459666 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01459666 about?
NCT01459666 is a clinical study titled "Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer". This study will test if the use of DysportTM (abobotulinumtoxinA) improves wound healing and scarring after Mohs surgery. Research in the laboratory as well as previous studies in humans have shown improved wound healing and scarring with the use of a similar medication called Botox. Dysport may im...
What is the current status of trial NCT01459666?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 9 participants. The study started on 2011-09. Estimated completion is 2019-08.
What interventions are being tested in trial NCT01459666?
The interventions under investigation include: Dysport (abobotulinumtoxinA) (DRUG), Bacteriostatic 0.9% Sodium Chloride (vehicle) (DRUG).
Who is sponsoring clinical trial NCT01459666?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.